Clinical Trial Update: Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial sponsored by the National Cancer Institute evaluated alisertib for relapsed or refractory peripheral T-cell non-Hodgkin lymphoma, with results p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Angioimmunoblastic T-cell Lymphoma
• Extranodal Nk T-cell Lymphoma Nasal Type
• Hepatosplenic T-cell Lymphoma
• Mature T-cell and Nk-cell Non-hodgkin Lymphoma
• Non-hodgkin Lymphoma
• Peripheral T-cell Lymphoma
• T-cell Leukemia Lymphoma

Drugs mentioned

• Alisertib (alisertib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Nasal Type Extranodal NK/T-Cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2016-03-10